Sulindac
Specifications
38194-50-2CAS Number
253-819-2EC Number
2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acidIUPAC Name
C20H17FO3SChemical Formula
356.4 g/molMolecular Weight
sulindac; 38194-50-2; Clinoril; Arthrocine; Artribid; Sulindaco; Sulindacum; Aflodac; Citireuma; Sulindac sulfoxide; Sulreuma; Imbaral; MK-231; Algocetil; Clisundac; Reumofil; Sulinol; Sudac; MK 231; cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; DTXSID4023624; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; 184SNS8VUH; NSC-757344; CHEBI:9352; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (Z)-; 2-[(1Z)-5-fluoro-1-[(4-methanesulfinylphenyl)methylidene]-2-methyl-1H-inden-3-yl]acetic acid; DTXCID703624; Klinoril; (Z)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; Reumyl; Chibret; Novo Sundac; Novo-Sundac; Nu Sulindac; Apo Sulin; Apo-Sulin; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-, (1Z)-; 1H-INDENE-3-ACETIC ACID, 5-FLUORO-2-METHYL-1-((4-(METHYLSULFINYL)PHENYL)METHYLENE)-, (1Z)-; MK231; 2-((1Z)-5-fluoro-1-((4-methanesulfinylphenyl)methylidene)-2-methyl-1H-inden-3-yl)acetic acid; RefChem:56287; M01AB02; (Z)-5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; cis-5-fluoro-2-methyl-1-(p-(methylsulfinyl)benzylidene)indene-3-acetic acid; (1Z)-(5-Fluoro-2-methyl-1-(4-((RS)-methylsulfinyl)benzylidene)-lH-inden-3-yl)acetic acid; 253-819-2; (Z)-2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetic acid; Mobilin; C20H17FO3S; CHEMBL15770; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; s2007; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; NCGC00015970-02; CAS-38194-50-2; MFCD00599589; Sulindacum [INN-Latin]; Sulindaco [INN-Spanish]; cis-Sulindac; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylene]inden-1-yl]acetic acid; Clinoril (TN); CCRIS 3305; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; SR-01000075237; EINECS 253-819-2; UNII-184SNS8VUH; BRN 2951842; Moblilin; Sulindac CRS; (Z)-2-[5-Fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl]acetic Acid; 2-(5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylene}inden-3-yl)acetic acid; 1H-Indene-3-aceticacid, 5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-, (1Z)-; EINECS 250-893-8; EINECS 256-402-3; Sulindac (Standard); Sulindac [USAN:USP:INN:BAN:JAN]; Tocris-1707; SULINDAC [USAN]; SULINDAC [INN]; SULINDAC [JAN]; SULINDAC [MI]; SULINDAC [VANDF]; Prestwick3_000073; Spectrum5_001024; Lopac-S-8139; SULINDAC [MART.]; SULINDAC [USP-RS]; SULINDAC [WHO-DD]; S 8139; Sulindac, >=98.0%; SCHEMBL4202; Lopac0_001070; BSPBio_000285; BSPBio_002890; MLS001056554; Sulindac - Bio-X trade mark; SPECTRUM1500556; Sulindac (JP18/USP/INN); SULINDAC [ORANGE BOOK]; BPBio1_000315; GTPL5425; orb1225145; orb1310592; SULINDAC [EP MONOGRAPH]; SCHEMBL29360981; SULINDAC [USP MONOGRAPH]; CHEBI:93811; HMS501O03; HY-B0008R; HLX0201; MSK7166; (S,Z)-2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetic acid; cMAP_000021; GLXC-20079; HMS1921C11; HMS2092K15; HMS2095O07; HMS2231N24; HMS3259K06; HMS3263E22; HMS3414N11; HMS3649P19; HMS3678N09; HMS3712O07; HMS3884K18; HMS5080B15; Pharmakon1600-01500556; HLX-0201; HY-B0008; Sulindac for system suitability CRS; Tox21_110270; Tox21_301418; Tox21_501070; BDBM50012899; BDBM50103504; CCG-39264; EBC-11159; MSK7166-100A; NSC757344; s8145; SBB058181; AKOS015895412; cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidenyl)indene-3-acetic acid; MSK7166-1000A; Sulindac 100 |Ig/mL in Acetonitrile; Tox21_110270_1; CS-0569; DB00605; FS27969; KS-5153; LP01070; NC00540; NSC 757344; SDCCGSBI-0051040.P005; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; IDI1_000601; Sulindac 100 microg/mL in Acetonitrile; NCGC00015970-01; NCGC00015970-03; NCGC00015970-04; NCGC00015970-05; NCGC00015970-06; NCGC00015970-07; NCGC00015970-08; NCGC00015970-11; NCGC00025268-01; NCGC00025268-02; NCGC00025268-03; NCGC00094349-01; NCGC00094349-02; NCGC00255143-01; NCGC00261755-01; NCGC00381714-10; BP-30208; BS166205; LS-14757; SMR000326718; SY075375; SBI-0051040.P004; Sulindac, meets USP testing specifications; AB00513800; cis-5-Fluoro-2-methyl-1-[(p-methylsulfiny; EU-0101070; NS00006901; ST51015123; Sulindac Solution in Acetonitrile, 100ug/mL; SW219748-1; U0099; Sulindac Solution in Acetonitrile, 1000ug/mL; C01531; D00120; AB00052105-07; AB00052105_08; AB00052105_09; EN300-7363233; F219743; Q963093; SR-01000075237-2; SR-01000075237-3; SR-01000075237-5; SR-01000075237-7; BRD-A13946108-001-04-9; BRD-A13946108-001-08-0; BRD-A13946108-001-16-3; BRD-A13946108-001-17-1; BRD-A13946108-001-18-9; BRD-A13946108-001-19-7; SR-01000075237-13; Sulindac, European Pharmacopoeia (EP) Reference Standard; Sulindac, United States Pharmacopeia (USP) Reference Standard; (1Z)-5-Fluoro-2-methyl-1-[(4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[(p-methylsulfinyl)benzylidene]-1H-indene-3-acetic Acid; (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)-phenyl]methylene]-1H-indene-3-acetic acid; {(1z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-indene-3-yl}acetic acid; [(1E)-5-Fluoro-1-{[4-(methanesulfinyl)phenyl]methylidene}-2-methyl-1H-inden-3-yl]acetic acidSynonyms
